Jove
Visualize
Contact Us

Related Experiment Videos

[Human immunodeficiency virus infection].

Hidetaka Fukue1, Tuyosi Oishi

  • 1Clinical Department of Infectious Diseases, Tokyo Medical University, Kasumigaura Hospital.

Rinsho Byori. the Japanese Journal of Clinical Pathology
|March 26, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Comparison of antimicrobial use density (AUD) of carbapenem antibacterial agents and investigation of the drug susceptibility of Pseudomonas aeruginosa in 3 hospitals in southern Ibaraki Prefecture, Japan].

Rinsho byori. The Japanese journal of clinical pathology·2008
Same author

[Factor XIII].

Nihon rinsho. Japanese journal of clinical medicine·2005
Same author

Surveillance of vancomycin-resistant Enterococcus in hospitals in Ibaraki prefecture.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy·2004
Same journal

[The Role of Laboratory Medicine in Hematopoietic Stem Cell Transplantation "Echocardiogram"].

Rinsho byori. The Japanese journal of clinical pathology·2019
Same journal

[The Significance of Pulmonary Function Testing Before and After Allogeneic Stem Cell Transplantation].

Rinsho byori. The Japanese journal of clinical pathology·2019
Same journal

[Blood Transfusion Inspection].

Rinsho byori. The Japanese journal of clinical pathology·2019
Same journal

[The Role of Clinical Laboratory Technicians at Bone Marrow Transplantation : Blood Test].

Rinsho byori. The Japanese journal of clinical pathology·2019
Same journal

[The Foundation of Allogeneic Hematopoietic Stem Cell Transplantation and the Role of Clinical Laboratory Tests in This Field].

Rinsho byori. The Japanese journal of clinical pathology·2019
Same journal

[How to Interpret Data from Routine Laboratory Tests].

Rinsho byori. The Japanese journal of clinical pathology·2019
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Plasma HIV RNA viral load and drug resistance testing are crucial for managing HIV-1 antiretroviral therapy. These assays inform treatment decisions, monitor patient status, and guide therapy to maximize benefits and prevent disease progression.

Area of Science:

  • Virology
  • Immunology
  • Pharmacology

Context:

  • Antiretroviral therapy (ART) is central to managing Human Immunodeficiency Virus type 1 (HIV-1) infection.
  • Clinical decisions regarding ART initiation and modification require robust diagnostic information.
  • Patient management necessitates understanding virologic and immunologic status to predict disease progression, including Acquired Immunodeficiency Syndrome (AIDS).

Purpose:

  • To underscore the importance of plasma HIV RNA (viral load) and drug resistance assays in guiding HIV-1 treatment decisions.
  • To highlight how these laboratory tests provide critical data on patient virologic and immunologic status.
  • To emphasize the role of resistance testing in optimizing ART efficacy and mitigating treatment failure.

Summary:

Related Experiment Videos

  • Plasma HIV RNA (viral load) and drug resistance assays are essential for managing HIV-1 infection.
  • Genotyping detects resistance mutations, while phenotyping measures viral drug susceptibility.
  • These tests inform decisions on initiating or changing antiretroviral therapy, thereby maximizing treatment benefits.

    • Impact:

    • Improved patient outcomes through optimized and personalized antiretroviral therapy regimens.
    • Enhanced ability to predict and manage treatment failure in HIV-1 patients.
    • Better clinical decision-making for physicians managing HIV-1 infection, leading to improved public health.
    • Maximizing the long-term benefits of antiretroviral therapy by addressing drug resistance proactively.